Don't get me wrong, I am not a basher. I am heeeeeeeavily invested on ONCS, but this Milestone starts to smell like a dead rat in the closet. There has been a promise about partnering Neopulse for more than half a year, and still nothing...which honestly speaking, smells.
What are your comments on this?
Sentiment: Strong Buy
I understand your frustration. Though I feel confident that this company is a true jewel in the space---and patience will be rewarded. Remember that this company is successfully treating melanoma and I, for one, am glad to stand behind the company as it progresses.
Sentiment: Strong Buy
i would like to bump this, and get other peoples opinion. I feel it is key. Either something happens here, or we have been lied... they must have a super hiper mega partnership deal for neopulse and immuno, right?? haha ;)
come on, the rest of the usual people share your thoughts!
I actually spoke to Amy about this on the phone a couple weeks ago. She said, and I quote, "Immunopulse has always been Punit's baby." She then went on to say that Neopulse is still part of their portfolio, and that by now focusing on Immunopulse they are "derisking" themselves in the eyes of potential partners/buyers. In other words, by expanding their platform, potential partners/buyers will see them as a less risky company to get involved with.
That could of course be BS, but if we can't rely on what Amy tells us, who can we rely on?
I know it sucks guys, but RISK = REWARD.
triat....NeoPulse is NOT a priority for them! I think they thought getting a partner for NeoPulse was going to be easier than it turned out. That is why they didn't even mention it when they announced their 2013 milestones.....they consider it 'gravy' at this point. It has almost been about a year since they said they were expecting a partner for it. The future of ONCS
ONCS swept NeoPulse under the carpet.. yes, they did miss there milestone of Q1 2013.. It is obvious they are focusing on ImmunoPulse ... I would have liked to have seen a follow up to thursday late buying... that was disconcerting...Let's hope dilution isn't around the corner next week... It was Amy who told me last time they diluted that they had plenty of cash until mid yr.. Lie... ..good luck longs
Bleomycin (sp?) is an old Cancer drug. Immunotherapy is where it's at. ONCS knows this and that's why they moved to IL-12 production and now are moving into PD-1 production.
We have to keep up with the times and ONCS is demonstrating with action that they are keeping up.
electroporation was already beyond the times they just have new potential to knock merck on their #$%$ with their own pd1 inhibitor
the basis for electroporation for melanoma is incredibly potent once you expand horizontally and add new elements with new moa's this is very logical